Is there still room for anti-angiogenic agents in small cell lung cancer?

Matteo Brighenti, Marcello Tiseo


We thank the authors of the editorials (1-4) in Transl Cancer Res for their comments on the GOIRC-AIFA FARM6PMFJM trial (5). This is the first randomized prospective phase III study assessing the role of adding bevacizumab to standard platinum-etoposide chemotherapy on survival outcome in the first-line treatment of extensive stage (ES) small cell lung cancer (SCLC).